

# Topical Collection

## Feature Papers in Gene and Cell Therapy

### Message from the Collection Editor

Recent progresses in gene and cell therapies have been the incentive for this *Biomedicine* «Feature Papers in Gene and Cell Therapy» Topical Collection.

Contributions from the editorial board members, as well as from distinguished scholars in this rapidly growing field will be acknowledged. Among the recent achievements in the field of gene therapy, CRISPR-directed gene edition has now reached clinical translation, with promising data in the treatment of sickle-cell anemia and transthyretin amyloidosis. Contributions addressing fundamental or clinical researches dealing with nucleic acids-based strategies from oligonucleotides to mRNAs and DNAs, as well as key issues on viral or non-viral delivery vectors will be welcomed. Cell therapy-based strategies also offer a great potential for the treatment of human diseases. As an example, pluripotent stem cells can be generated from somatic cells with the capacity to proliferate indefinitely and to be reprogrammed for differentiation at will. Contributions dealing with various aspects and applications of cell-based strategies will be welcomed, from animal models to human diseases clinical studies.

### Collection Editor

Dr. Bernard Lebleu

Laboratory of Pathogen Host Interactions, Biology-Health Department, Montpellier University, Montpellier, France



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/117519](https://mdpi.com/si/117519)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).